Escrito por Dr. Maria do Carmo Costa, editado por Dr. Hayley McLoughlin. Inicialmente publicado em 24 de abril de 2020. Traduzido para o português por Priscila P. Sena. Em um trabalho de colaboração utilizando modelo animal, pesquisadores de Portugal e do Reino Unido descobrem um subproduto do óleo de canola Read More…
Written by Brenda Toscano Marquez Edited by Marija Cvetanovic Insoluble clumps of mutated ataxin-1 capture essential proteins and trigger the creation of toxic reactive oxygen species. All proteins produced by our cells consist of long chains of amino acids that are coiled and bent into a particular 3D structure. Changes Read More…
March 2023 Update: SKYCLARYS™ (Omaveloxolone) has become the first FDA-approved treatment for Friedreich’s Ataxia. You can learn more about SKYCLARYS™ at this link. This Snapshot was written in May 2020 after initial positive results were shared about Omaveloxolone. A new therapeutic compound shows promise to treat Friedrich’s ataxia. What is Read More…
Written by Dr. Maria do Carmo Costa, Edited by Dr. Hayley McLoughlin Collaboration between researchers in Portugal and the United Kingdom discover that a canola oil by-product shows promise, corrects MJD/SCA3 and Parkinson’s Disease symptoms in animal models. Isolated compounds or extracts (containing a mixture of compounds) from certain plants are Read More…
Written by Dr. Judit M. Pérez Ortiz Edited by Dr. Brenda Toscano Márquez Scientists describe how SCA2 oxidative stress can affect mitochondrial function, and potentially how to fix it Mitochondrial Stress We all have experienced stress. When cramming for an exam last minute, or getting ready for a job interview, Read More…
Written by Siddharth Nath Edited by Dr. Ray Truant Oxidative stress is a hot topic in neurodegenerative disease research. New findings from Dr. Jonathan Magaña’s lab in Mexico show increases in measures of damage from oxygen compounds in SCA7 patients versus healthy individuals. This suggests that this type of chemical stress may Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.
501(c)(3)
EIN 41-0832903
Mailing Address:
PO Box 27986
Golden Valley, MN 55427
Physical Address:
600 Highway 169 South
Suite 1725
Minneapolis, MN 55426
763-553-0020
763-553-0167 (Fax)
